Literature DB >> 11497346

Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.

P L Iversen1.   

Abstract

The phosphorodiamidate morpholino oligomers (PMOs) are a distinct class of oligonucleotide analogs. They bind to RNA and efficiently interfere with gene expression in a sequence-specific manner. Their non-ionic character combined with resistance to degradation in the body offer efficacy with minimal toxicity. Hence, the PMOs are emerging as an excellent approach to therapeutics that can be rationally designed based on target gene sequence data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11497346

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  25 in total

1.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Modulation of polycystic kidney disease by non-coding RNAs.

Authors:  Harini Ramalingam; Matanel Yheskel; Vishal Patel
Journal:  Cell Signal       Date:  2020-01-23       Impact factor: 4.315

Review 3.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

4.  Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis.

Authors:  Rekha G Panchal; Bruce L Geller; Brett Mellbye; Douglas Lane; Patrick L Iversen; Sina Bavari
Journal:  Nucleic Acid Ther       Date:  2012-09-14       Impact factor: 5.486

5.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

6.  Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats.

Authors:  Vikram Arora; Tracy L Hannah; Patrick L Iversen; Rhonda M Brand
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 7.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

8.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 9.  On future's doorstep: RNA interference and the pharmacopeia of tomorrow.

Authors:  Alan M Gewirtz
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Authors:  Dana L Swenson; Kelly L Warfield; Travis K Warren; Candace Lovejoy; Jed N Hassinger; Gordon Ruthel; Robert E Blouch; Hong M Moulton; Dwight D Weller; Patrick L Iversen; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.